http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003035797-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb8f3eba86915d967beefc175437273a
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4266
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42
filingDate 2002-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc219a9a5ce0d3e6cafcda521bfc23b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_001c1c2175b1720c2e35c21abfb6726f
publicationDate 2003-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2003035797-A1
titleOfInvention Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
abstract The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100968936-B1
priorityDate 1992-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4918164-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4849509-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6632431-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5126262-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE32833-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4900547-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6805862-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5493009-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5270202-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5792455-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5529922-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6235280-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10444661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID378
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129356837
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11787
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11459
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135990222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421592
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128548416
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129763036
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465496165
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58600231
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396022
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10149006
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4686862
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421590

Total number of triples: 45.